Charting new paradigms for CAR-T cell therapy beyond current Achilles heels
Y Li, Z Hu, Y Li, X Wu - Frontiers in Immunology, 2024 - frontiersin.org
Chimeric antigen receptor-T (CAR-T) cell therapy has made remarkable strides in treating
hematological malignancies. However, the widespread adoption of CAR-T cell therapy is …
hematological malignancies. However, the widespread adoption of CAR-T cell therapy is …
The present and future for CAR-T cell therapy in adult B-cell ALL
C Roddie, A Rampotas - Blood Journal, 2024 - ashpublications.org
Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has transformed the
management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA …
management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B-ALL), with FDA …
The present and future for CAR-T cell therapy in adult B-cell ALL
A Rampotas, C Roddie - Blood, 2024 - Elsevier
ABSTRACT Chimeric Antigen Receptor T-cell therapy (CAR-T) targeting CD19 has
transformed the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B …
transformed the management of relapsed/refractory (r/r) B-Acute Lymphoblastic Leukemia (B …
[PDF][PDF] 1 Prognostic factors and outcome of patients with lymphoproliferative disorders who receive treatment with chimeric antigen receptor T-cells
GI Iacoboni García-Calvo - 2023 - ddd.uab.cat
The dismal prognosis of patients with relapsed/refractory large B-cell lymphoma has
significantly improved since the advent of CAR T-cell therapy. Despite these enormous …
significantly improved since the advent of CAR T-cell therapy. Despite these enormous …